Boehringer Ingelheim has received the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award' from Frost & Sullivan. The analysts recognized Boehringer Ingelheim Biopharmaceuticals as a global contract manufacturer who delivers excellence and best practices to its customers and collaboration partners. The Boehringer Ingelheim performance was measured against key competitors in the same market focusing on the criteria: leverage of competitive intelligence, execution of competitive strategy, impact on market share, competitive brand positioning and impact on customer satisfaction and value.
"This award is an important recognition for our contract manufacturing organization and a great confirmation for continued drive to put our customers first", stated Simon Sturge, Corporate Senior Vice President Biopharmaceuticals at Boehringer Ingelheim. "We will not rest on our laurels and will continue to further improve our customer services to also deliver reliable and best quality in the future. With our newly acquired biopharma development- and manufacturing facility in Fremont, California, Boehringer Ingelheim has already taken the next important step to further strengthen our global customer orientation and flexibility."
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since its foundation in 1885, the family-owned company has been committed for more than 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.